Hans-Christian Kolberg, MD

Articles by Hans-Christian Kolberg, MD

Dr. Hans-Christian Kolberg on Safer Chemotherapy for Patients with HER2-positive Early Breast Cancer

October 29th 2015

Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab for patients with HER2-positive early breast cancer.

Latest Updated Articles

Dr. Hans-Christian Kolberg on Safer Chemotherapy for Patients with HER2-positive Early Breast Cancer
Published: October 29th 2015 | Updated:

Hans-Christian Kolberg, MD

Articles by Hans-Christian Kolberg, MD

Dr. Hans-Christian Kolberg on Safer Chemotherapy for Patients with HER2-positive Early Breast Cancer

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma